###### Clinical Perspective

What Is New?
============

-   The yield of testing for pathogenic disease-causing genetic mutations in athletes exhibiting T-wave inversion is low (10%), despite the use of a comprehensive genetic panel.

-   Gene testing in selected athletes referred to a tertiary referral center contributes to additional diagnoses beyond comprehensive clinical evaluation in only 2.5% of athletes with T-wave inversion without a clear clinical phenotype.

-   The overall diagnostic yield from genetic testing in athletes with T-wave inversion is one half that of comprehensive clinical evaluation (21% versus 10%).

-   The prevalence of cardiomyopathy in white athletes with T-wave inversion is higher compared with black athletes with T-wave inversion (30% versus 12%).

What Are the Clinical Implications?
===================================

-   Genetic testing is rarely useful in the routine investigation of athletes with T-wave inversion who have undergone comprehensive clinical evaluation.

-   In contrast, comprehensive clinical evaluation can identify a clinical diagnosis in more than one fifth of athletes with T-wave inversion on initial evaluation, with a higher probability of a clinical diagnosis in white compared with black athletes (30.0% versus 12%).

-   This study demonstrates that lateral T-wave inversion in an athletic population referred to a specialized athletic center is associated with cardiac disease in 20% of athletes.

**Editorial, see p 1206**

A small proportion of apparently healthy adult athletes exhibit marked repolarization abnormalities in the absence of detectable structural heart disease. Of these repolarization patterns, most interest has focused on T-wave inversion (TWI),^[@R1]--[@R9]^ which is a common manifestation of several inherited cardiomyopathies and some ion channel diseases implicated in sudden cardiac death.

Although rare in adult white athletes,^[@R10]--[@R14]^ TWI is observed in up to one quarter of athletes of African/Afro-Caribbean descent (black athletes) and most commonly confined to the anterior leads (V~1~--V~4~).^[@R3],[@R5]^ Observational data suggest that this specific repolarization pattern represents a benign, ethnic manifestation of the athlete's heart.^[@R3],[@R5],[@R15]^ In contrast, the clinical significance of inferior and lateral TWI is less certain. Recent studies using cardiac magnetic resonance imaging (CMR)^[@R4]^ and longitudinal follow-up^[@R1],[@R3],[@R6]^ in athletes with inferior or lateral TWI have reported an association with these repolarization changes and cardiomyopathy, risk of sudden cardiac arrest, or the subsequent development of cardiomyopathy over time. The majority of athletes in these studies, however, failed to reveal any demonstrable cardiac pathology. None of these studies incorporated genetic testing to help determine whether TWI represented an early, subtle, or concealed manifestation of cardiomyopathy or ion channel disease. Genetic testing was previously expensive and impractical, but next-generation sequencing^[@R16]^ has now offered major advances in the molecular genetics of inherited cardiac diseases and the development of relatively inexpensive genetic panels to investigate a broad spectrum of recognized mutations in genes implicated in cardiomyopathy and ion channel disorders.

The aim of this study was to examine the additional diagnostic yield for these genetic diseases beyond standard comprehensive clinical evaluation in highly trained black and white athletes with TWI using a wide genetic panel.

Methods
=======

Setting
-------

The charitable organization Cardiac Risk in the Young (CRY) provides a national preparticipation screening service for several elite national sporting bodies and regional teams, including Aviva Premiership Rugby, British Rowing, English cricket, English Institute of Sport, Lawn Tennis Association, Rugby Football Union, and several Premiership soccer clubs. Athletes with abnormal findings undergo further investigations, of which \>80% are conducted in the Sports Cardiology Unit at St. George's Hospital. The principal investigator (S.S.) also receives referrals directly to the sports cardiology unit from other elite professional sporting bodies and other medical institutions throughout the United Kingdom. Since 2010, we have also received referrals from Qatar Orthopedic and Sports Medicine Hospital (Doha, Qatar), which has a highly active cardiovascular screening program that serves the entire Persian Gulf region. All elite athletes receive a 12-lead ECG and 2-dimensional echocardiography as part of these screening programs.

The data, analytical methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.

Study Design and Recruitment of Athletes
----------------------------------------

Between April 2012 and April 2014, a total of 2039 athletes (260 black and 1779 white) were evaluated. Fifty consecutive black and 50 consecutive white athletes 14 to 35 years of age with TWI ≥−0.1 mV in ≥2 contiguous leads (excluding aVR, V~1~, and lead III in isolation) were prospectively recruited into the study. Twenty-seven athletes were recruited through preparticipation cardiac evaluation performed by CRY in the United Kingdom and 14 through preparticipation cardiac evaluation performed by Qatar Orthopedic and Sports Medicine Hospital in Doha. The remainder (n=59) were recruited after direct referral to St. George's Hospital for evaluation of TWI on clinical grounds from another institution or a professional sporting body in the United Kingdom. Exclusion criteria for recruitment into the study included cardiac symptoms or a family history of cardiomyopathy or ion channel disease, a cardiac history, a medical history of hypertension, use of anabolic steroids or performance-enhancing drugs, and a structurally abnormal heart or wall motion abnormalities on echocardiography.

Ethics Approval and Informed Consent
------------------------------------

Ethics approval was obtained from the local ethics committee in accordance with the Declaration of Helsinki.^[@R17]^ Written consent for enrollment of participants was obtained from individuals ≥16 years of age and from a parent or guardian for those \<16 years of age. Genetic testing is not routinely performed for the evaluation of athletes in the United Kingdom, and current European guidelines recommend disqualification of genotype-positive, phenotype-negative individuals from competitive sports.^[@R13]^ Therefore, the results of genetic testing were not given to the athlete or sports organization unless the athlete specifically requested the result after appropriate counseling and informed consideration of a positive test on the athlete's career.

Clinical Investigations in Athletes
-----------------------------------

All athletes were also investigated with 12-lead ECG, signal-averaged ECG, cardiopulmonary exercise stress testing, 24-hour ambulatory electrocardiographic monitoring, and CMR.

### 12-Lead ECG

Standard 12-lead ECG was performed with a MAC 5000 or MAC 5500 digital resting electrocardiographic recorder (GE Medical Systems, Milwaukee, WI) and analyzed as previously described.^[@R18]^ TWI of ≥−0.1 mV in ≥2 contiguous leads was considered significant, other than in leads V~1~, aVR, and III. The distribution of TWI was classified into 3 groups: TWI confined to the anterior leads (V~1~--V~4~); TWI involving the inferior leads (II, III, aVF), with or without anterior TWI; or TWI involving the lateral leads (I, aVL, V~5~, V~6~), regardless of TWI in the other leads.

### Signal-Averaged ECG

Signal-averaged ECG was acquired according to accepted methodology^[@R19]^ with a MAC 5000 or MAC 5500 digital resting ECG recorder.

### Cardiopulmonary Exercise Stress Testing

Cardiopulmonary exercise testing was performed in an upright position with a COSMED E100w cycle ergometer (Rome, Italy) as previously described^[@R20]^ using an incremental ramp protocol of 30 W/min in a quiet, air-conditioned room with an average temperature of 21°C and full resuscitation facilities. Subjects were encouraged to exercise to the point of exhaustion. Breath-by-breath gas exchange analysis was performed with a dedicated COSMED Quark CPEX metabolic cart. Blood pressure was measured before the test and then at 3-minute intervals with an automated cuff. Signals from a 12-lead ECG were displayed continuously and recorded at 2-minute intervals with a COSMED Quark C12x electrocardiographic recorder.

### 24-Hour Ambulatory Electrocardiographic Monitoring

Twenty-four-hour ambulatory electrocardiographic monitoring (Lifecard CF Holters, Spacelabs Healthcare, Snoqualmie, WA) was performed specifically to detect supraventricular and ventricular arrhythmias.^[@R21]^ Nonsustained ventricular tachycardia was defined as ≥3 consecutive ventricular beats at a rate of \>120 bpm with a duration of \<30 seconds.

### Cardiac Magnetic Resonance Imaging

CMR was performed with previously described methods and analyzed with semiautomated software.^[@R7]^ All volumes and masses were indexed for age and body surface area according to the Du Bois and Du Bois^[@R22]^ formula. Late gadolinium images were acquired after intravenous gadolinium-DTPA administration.^[@R7]^ The presence or absence of late gadolinium enhancement (LGE) was recorded as a binary variable.

Candidate Disease and Gene Selection for Genetic Testing
--------------------------------------------------------

Genetic testing was performed for priority genes responsible for 6 inherited cardiac conditions most commonly associated with TWI, namely hypertrophic cardiomyopathy (HCM),^[@R23]^ arrhythmogenic right ventricular cardiomyopathy,^[@R24]^ dilated cardiomyopathy,^[@R25]^ left ventricular (LV) noncompaction (LVNC),^[@R26]^ long-QT syndrome (LQTS),^[@R27],[@R28]^ and Brugada syndrome.^[@R29]^ To ensure that comprehensive genetic evaluation was performed, a large number of potential candidate genes were also tested after a systematic literature review. Overall, a total of 104 genes for HCM (including phenocopies), 21 genes for arrhythmogenic right ventricular cardiomyopathy, 96 genes for dilated cardiomyopathy, 37 genes for LVNC, 28 genes for LQTS, and 25 genes for Brugada syndrome were tested ([Table I in the online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.034208)).

Definitions of Clinical Diagnoses
---------------------------------

The diagnosis of a cardiomyopathy (HCM, arrhythmogenic right ventricular cardiomyopathy, dilated cardiomyopathy, and LVNC) or an ion channel disorder (LQTS and Brugada syndrome) was made in accordance with internationally recognized guidelines.^[@R23],[@R29]--[@R31]^ In particular, the diagnosis of HCM was based on LV hypertrophy (LVH) ≥15 mm in any myocardial segment, as assessed on CMR, in the absence of another cardiac disorder or systemic condition capable of producing the same magnitude of LVH.^[@R32],[@R33]^ In cases of mild LVH, HCM was diagnosed in the context of a combination of features, including nonconcentric patterns of LVH; LGE on CMR; an established or likely pathogenic gene mutation; the presence of broader phenotypic features of the condition such as nonsustained ventricular tachycardia or a blunted blood pressure response to exercise; and, in the case of apical HCM, the appearance of relative apical hypertrophy and cavity obliteration out of keeping with athletic training in combination with typical lateral deep TWI.^[@R34]--[@R36]^ Phenocopies of HCM were diagnosed on the basis of the above criteria and confirmation by a relevant pathogenic genetic test. The diagnosis of LVNC was based on increased trabeculation of the LV myocardium fulfilling recognized CMR criteria^[@R37]^ and the concurrent presence of wall thinning or LV systolic dysfunction.

Genetic Testing in Athletes
---------------------------

### Sample Preparation, Genetic Sequencing, and Analysis

Genomic DNA was extracted from 1 mL peripheral blood samples. Sequencing of all coding exons and intronic flanking regions was performed through massive parallel sequencing technology. Targeted enrichment of the genes associated with each condition was performed. Sample preparation was conducted with the SureSelect Target Enrichment Kit (Agilent, California, Santa Clara, CA) for Illumina (San Diego, CA) paired-end multiplexed sequencing method, following the manufacturer's instructions. Regions of interest were captured with a custom probe library. Sequencing was performed on an Illumina HiSeq 1500 with 2×100 base read length following Illumina protocols. Low-coverage regions (defined as every base with depth of coverage \<15×) in those genes related to the diseases in question were resequenced through the Sanger method. Bioinformatic analysis was performed by means of a custom pipeline that included Novoalign (Novocraft, Selangor, Malaysia), Samtools (Genome Research Ltd, Wellcome Trust Sanger Institute, Hinxton, UK), Genome Analysis Toolkit (Broad Institute, Cambridge, MA), and bcftools (Genome Research Ltd) for variant calling and genotyping and Annovar for variant annotation.

### Determination of Variant Frequency

Information on the frequency of identified genetic variants in different populations was analyzed from (1) the Exome Variant Server, National Heart, Lung, and Blood Institute GO Exome Sequencing Project, Seattle, WA (<http://evs.gs.washington.edu/EVS/>); (2) the 1000 Genomes Project ([www.1000genomes.org/](www.1000genomes.org/)); (3) the Database of Single Nucleotide Polymorphisms, National Center for Biotechnology Information, US National Library of Medicine, Bethesda, MD (<https://www.ncbi.nlm.nih.gov/snp/>); (4) the Human Gene Mutation Database^[@R38]^ ([www.hgmd.cf.ac.uk](www.hgmd.cf.ac.uk)); (5) ClinVar^[@R39]^; and (6) the Exome Aggregation Consortium, Cambridge, MA, and the Genome Aggregation Database (<http://exac.broadinstitute.org>, and <http://gnomad.broadinstitute.org>).

### Definitions and Pathogenicity of Identified Variants

Identified variants were classified as mutations if absent in control populations, rare variants if present in \<1% of control populations, and polymorphisms if present in ≥1% of control populations. The pathogenicity of the identified variants was classified according to current recommendations from the American College of Medical Genetics and Genomics.^[@R40]^ In summary, variants were considered potentially pathogenic if they were absent or rare in healthy control subjects, previously associated with disease development, and functionally relevant variants in genes previously associated with the identified phenotype (eg, in-frame or frameshift-causing insertions or deletions, variants affecting splice sites, or missense variants likely to be pathogenic as identified by software models such as SIFT,^[@R41]^ PolyPhen,^[@R42]^ and MutationTaster2^[@R43]^). A detailed description of the methods used to determine pathogenicity of identified variants is summarized in [Table II in the online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.034208).

Statistical Analysis
--------------------

The Kolmogorov-Smirnov test was used to evaluate whether each continuous parameter followed a gaussian distribution. Values are expressed as absolute numbers and percentages for categorical data and mean±SD for continuous data. Comparisons were performed with the χ^2^ test or Fisher exact test for categorical variables, unpaired *t* test for normally distributed continuous variables, and Mann-Whitney *U* test for nonnormally distributed continuous variables. A 2-tailed value of *P*\<0.05 was considered significant throughout. All analyses were performed with SPSS software, version 20.0 (IBM Analytics).

Results
=======

Athlete Demographics
--------------------

There were no differences between black and white athletes with respect to age, sex, body surface area, resting blood pressure, and hours of exercise per week (Table [1](#T1){ref-type="table"}). All athletes had a resting blood pressure of \<140/90 mm Hg. The majority of athletes (≥90%) in both groups were men.

###### 

Demographic Characteristics of Black and White Athletes
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Electrocardiographic Characteristics
------------------------------------

All athletes were in sinus rhythm. TWI extending into the lateral leads was the most common pattern of TWI in both black and white athletes, followed by TWI confined to the anterior leads V~1~ through V~4~ (Table [2](#T2){ref-type="table"}). Of note, there was a relatively high prevalence of pathological Q waves and ST-segment depression in both groups; ST-segment depression was observed in at least one fifth (Table [2](#T2){ref-type="table"}). Most athletes revealed 1 abnormal parameter on signal-averaged ECG, and 7 black (14%) and 6 white (12%) athletes revealed ≥2 abnormal parameters.

###### 

Electrocardiographic and Cardiac Magnetic Resonance Imaging Characteristics of Black and White Athletes
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Structural Characteristics on CMR
---------------------------------

Consistent with previous studies, white athletes had greater LV and right ventricular volumes on CMR compared with black athletes, whereas black athletes had a greater mean maximal LV wall thickness (Table [2](#T2){ref-type="table"}). Five black athletes (10%) and 5 white athletes (10%) revealed LGE.

Cardiopulmonary Exercise Testing and Holter Monitoring
------------------------------------------------------

Three athletes with HCM demonstrated an abnormal blood pressure response to exercise. Two athletes with HCM had a short run of nonsustained ventricular tachycardia. One athlete without a diagnosis of cardiomyopathy demonstrated transient asymptomatic atrioventricular reentrant tachycardia.

Diagnoses Based on Clinical Investigations
------------------------------------------

In total, 21 athletes (21%) were diagnosed with cardiac disease on the basis of comprehensive clinical investigation. HCM was the most common diagnosis and affected 19 of the 21 athletes (90.5%). The diagnosis of HCM was based predominately on the degree and segmental nature of LVH on CMR and LGE. One athlete (4.8%) with extracardiac features was diagnosed with Fabry disease (later confirmed on genetic testing), and 1 athlete (4.8%) was diagnosed with LVNC. A clinical diagnosis of cardiomyopathy was more common in white athletes compared with black athletes (30% versus 12%; *P=*0.027). One black athlete (2%) revealed LGE on CMR in the absence of a clear diagnosis.

Diagnostic Yield of Genetic Testing
-----------------------------------

A genetic variant was identified in 63 athletes (63%); however, only 10 athletes revealed a disease-causing variant (pathogenic mutation \[n=4\] or variant of likely pathogenicity \[n=6\]), including 7 (14%) white athletes and 3 (6%) black athletes (Figure [1](#F1){ref-type="fig"} and Table [3](#T3){ref-type="table"}). The remaining 53 athletes were considered to have variants of unknown significance.

###### 

Clinical Diagnoses Made in Athletes
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![**Breakdown of athletes with clinical and genetic diagnoses.** The diagnostic yield with comprehensive clinical investigation was 21% compared with 10% using genetic testing. Of the 21 athletes diagnosed with cardiac disease on the basis of clinical investigation, 8 (38.1%) were gene positive (myosin binding protein C\[*MYBPC3*\], myosin heavy chain 7 \[*MYH7*\], galactosidase alpha\[*GLA*\], and actin, alpha, cardiac muscle 1 \[*ACTC1*\] genes) and 13 (61.9%) were gene negative. Of the remaining 79 athletes without a clinical diagnosis, 2 (2.5%) were gene positive (transthyretin\[*TTR*\] and sodium voltage-gated channel alpha subunit 5 \[*SCN5A*\] genes) in the absence of a clinical phenotype. HCM indicates hypertrophic cardiomyopathy; LQTS, long-QT syndrome; and LVNC, left ventricular noncompaction.](cir-138-1184-g004){#F1}

Of the 21 athletes with a clinical diagnosis, 8 individuals (38.1%; 6 white and 2 black) had a positive gene test consistent with the diagnosis (Figure [1](#F1){ref-type="fig"} and Table [3](#T3){ref-type="table"}). Of these 8 athletes, 6 athletes (5 white and 1 black) were diagnosed with HCM; 1 white athlete was diagnosed with Fabry disease; and 1 black athlete was diagnosed with LVNC (Figure [1](#F1){ref-type="fig"} and [Table III in the online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.034208)).

Among the remaining 79 athletes without a clinical diagnosis, 2 (2.5%) were identified with a disease-causing variant in the absence of a clinical phenotype. Specifically, 1 white athlete had a likely pathogenic rare variant in the sodium voltage-gated channel alpha subunit 5 (*SCN5A*) gene previously reported to be associated with LQTS, and 1 black athlete had a pathogenic polymorphism in the transthyretin (*TTR*) gene that is found in up to 4% of black individuals and associated with the development of wild-type transthyretin amyloidosis.

Electric Changes in Athletes With a Cardiac Diagnosis
-----------------------------------------------------

Pathological Q waves and ST-segment depression were more common in athletes with cardiac disease compared with those without cardiac disease (Table [4](#T4){ref-type="table"}). Almost all athletes diagnosed with cardiac disease (n=20, 95.2%) revealed TWI in the lateral leads (Figure [2](#F2){ref-type="fig"}). TWI limited to the anterior leads was detected in just 1 white athlete (4.8%) with cardiac pathology (Figure [2](#F2){ref-type="fig"}). The same athlete also revealed coexisting pathological Q waves. None of the black athletes with anterior TWI was diagnosed with a cardiomyopathy or an ion channel disorder. One 23-year-old black athlete with anterior TWI harbored a pathogenic mutation in the *TTR* gene associated with wild-type transthyretin amyloidosis. None of the athletes with TWI confined to the inferior leads was diagnosed with cardiac disease or revealed a pathogenic genetic mutation.

###### 

Electrical, Structural, and Functional Characteristics of Athletes Diagnosed With Structural Cardiac Disease Compared With Those Without Cardiac Disease
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![**Comparison of clinical and genetic diagnoses in black and white athletes in relation to the distribution of T-wave inversion (TWI).** *ACTC1*indicates actin, alpha, cardiac muscle 1; *GLA*, galactosidase alpha; HCM, hypertrophic cardiomyopathy; LQTS, long-QT syndrome; LVNC, left ventricular noncompaction; *MYBPC3*, myosin binding protein C; *MYH7*, myosin heavy chain 7; *SCN5A*, sodium voltage-gated channel alpha subunit 5; and *TTR*, transthyretin.](cir-138-1184-g006){#F2}

Costs Per Diagnosis Associated With Clinical and Genetic Testing
----------------------------------------------------------------

The cost of clinical evaluation amounted to US\$1084 per athlete using standard National Health Service Tariffs and an exchange rate of £1 to US\$1.28. This figure equated to a cost of US\$5162 per athlete diagnosed with cardiac disease. Addition of genetic testing increased the cost of evaluation by 3-fold to US\$3267 per athlete, equating to a cost of US\$14 204 per athlete with a clinical or genetic diagnosis and a cost of US\$32 670 per genetic diagnosis alone. The cost of making additional diagnoses beyond clinical evaluation based on genetic testing (2 genotype-positive individuals without a clear clinical phenotype) was US\$109 150 per athlete.

Discussion
==========

The present study investigated whether genetic testing for mutations capable of causing cardiomyopathy and ion channel diseases has a potential role in determining the clinical significance of TWI in both black and white athletes over and above standard clinical evaluation.^[@R18]^ The cohort of athletes is unique, and recruitment was possible only through the assessment of a large number of athletes from several different referral sources. Although a total of 2039 athletes were evaluated in our own sports cardiology clinic over the 2-year study period, these individuals were referred from a pool of \>5400 athletes assessed by CRY and \>3000 athletes assessed by Qatar Orthopaedic and Sports Medicine Unit during the same study period. A significant proportion of athletes were also referred to us after being assessed at different institutions throughout the United Kingdom. Although it is more challenging to provide the precise denominator for this referral group, the majority of athletes in the present study (57%) revealed lateral TWI. On the basis of our own screening experience that only 4% of black^[@R3],[@R5]^ and 0.3% of white^[@R2],[@R3],[@R5]^ athletes in the United Kingdom reveal lateral TWI, we estimate that the total number of athletes required to derive a cohort of athletes with the TWI patterns described in this study would exceed 11 000.

Diagnostic Yield From Genetic Testing
-------------------------------------

The overall diagnostic yield from genetic testing for a pathogenic or likely pathogenic mutation in athletes with TWI was 10% compared with 21% after comprehensive clinical evaluation. Genetic testing was positive in just 8 athletes (38.1%) with a clinical diagnosis of cardiomyopathy despite a very comprehensive panel of genes being tested. Of these, 6 athletes (75.0%) were white. Genetic testing identified an additional 2 athletes (2.5%) with TWI but no clear clinical phenotype who harbored potential cardiac disease. Compared with a recent study by Kadota et al^[@R44]^ in which 5 of 102 Japanese athletes (4.9%) with electrocardiographic abnormalities screened for mutations in 4 sarcomeric genes (myosin heavy chain 7 \[*MYH7*\], myosin binding protein C\[*MYBPC3*\], troponin T2, cardiac type \[*TNNT2*\], and troponin 13, cardiac type \[*TNNI3*\]) showed a positive result, our yield was significantly higher and likely reflects the comprehensive genetic panel used.

The yield for pathogenic mutations in our athletes clinically diagnosed with HCM was half that expected from the published literature (32% versus ≈60%--70%). One third of the athletes diagnosed with HCM exhibited the apical variant, which has been shown to have a lower-than-usual genetic yield.^[@R45]^ The current false-negative rate of genetic testing in our cohort indicates that routine genetic testing in athletes with TWI who have undergone comprehensive clinical evaluation will support a possible diagnosis of cardiomyopathy in a few cases at a substantial cost. These observations do not support the routine use of genetic testing for the evaluation of asymptomatic athletes with TWI in the absence of a family history of an inherited cardiac condition.

Although genetic testing identified a potentially serious *SCN5A* mutation implicated in LQTS in a white female athlete with TWI, she did not show any features of the disorder, including a prolonged corrected QT interval. Similarly, gene testing identified a definitive transthyretin mutation in a black athlete without evidence of cardiac amyloidosis at this young age, and it is known that this variant is detected in up to 4% of the black population. These observations also highlight that routine gene testing without appropriate clinical indications may be confusing, cause unnecessary concern, and be problematic for decision making.

Association Between Pattern of TWI and Cardiac Pathology
--------------------------------------------------------

In both black and white athletes, TWI extending into the lateral leads was the most common pattern encountered (64% versus 50%, respectively; Figure [2](#F2){ref-type="fig"}). Although previous studies in both black and white athletes report anterior TWI (V~1~--V~4~) to be the most common pattern observed,^[@R3]^ our cohort almost certainly reflects a referral bias in favor of individuals with lateral TWI in whom suspicion of a cardiomyopathy is higher. Furthermore, given that anterior TWI is now widely recognized as a normal, ethnicity-specific training variant in black athletes, referral bias may also explain the similar prevalence of anterior TWI observed in our black and white cohorts, with fewer black athletes exhibiting anterior TWI being referred for evaluation.

ST-segment depression was found exclusively in athletes with lateral TWI, regardless of ethnicity. All but 1 of our 21 athletes (95%) exhibiting structural disease revealed lateral TWI (Table [3](#T3){ref-type="table"} and Figure [2](#F2){ref-type="fig"}). Indeed, the diagnostic yield of lateral TWI for a clinical diagnosis of cardiomyopathy in black and white athletes was 18.8% and 56%, respectively. In comparison, the yield for mutations associated with cardiomyopathy in athletes with lateral TWI was 12.3%.

Compared with white athletes, a smaller proportion of black athletes with TWI (n=6, 12%) were diagnosed with a cardiomyopathy (Table [3](#T3){ref-type="table"}). Of these individuals, all exhibited TWI in the lateral leads, reinforcing the notion that this particular repolarization pattern should be viewed with caution, even in the black athletic population in whom its prevalence approaches 5%.^[@R3]^ Anterior TWI in black athletes was not associated with overt cardiomyopathy, ion channel disorders, or pathogenic genetic mutations, suggesting that this pattern is likely benign.^[@R46]^

Overall Number of Diagnoses Made and Yield From CMR
---------------------------------------------------

Significantly fewer black athletes were diagnosed with a cardiomyopathy compared with white athletes (12% versus 30%; *P=0*.027), suggesting that TWI may be more representative of subtle forms of cardiomyopathy in white individuals. The only other study to comprehensively investigate athletes with TWI with CMR evaluated 155 athletes.^[@R4]^ The authors diagnosed 37 athletes with a cardiomyopathy (predominantly HCM) on initial echocardiography. Of the remaining 118, a further 24 athletes (20.3%) were diagnosed with CMR, a figure comparable to the 21 athletes (21.0%) diagnosed in the present study, and a further 3 athletes (2.5%) were diagnosed on the basis of Holter monitoring and exercise testing. In this study, Holter monitoring and exercise stress testing revealed the broader phenotypic features of HCM in over 26% of affected athletes.

Study Limitations
-----------------

The present study has several limitations. Inherited cardiomyopathies exhibit an age-related penetrance; thus, it is possible that cardiac disease was underdiagnosed in our cohort. Our population consisted of predominately young male athletes. Therefore, any conclusions about the significance of TWI in female or master athletes cannot be extrapolated from this study. It was also not possible to perform familial evaluation of first-degree family members, which would have been a valuable source of information to help determine the genetic significance of TWI in borderline cases, even in the absence of a pathogenic mutation. Cosegregation studies were not performed and would have been important to determine the pathogenicity of several of the identified variants. Finally, the absence of a pathogenic mutation does not exclude the possibility of underlying disease, and several athletes revealed variants of undetermined clinical significance; thus, long-term clinical follow-up is warranted.

Conclusions
-----------

Up to 10% of athletes with TWI show definitive or likely pathogenic mutations for cardiomyopathy or ion channel disease. Compared with standard clinical practice, the relatively low diagnostic yield and high cost of genetic testing make it of negligible use in routine clinical practice. Although genetic testing may help identify individual athletes with TWI and a potential cardiac disorder in the absence of a clear clinical phenotype, our results suggest that it is not indicated in the routine evaluation of asymptomatic athletes with TWI in the absence of a family history of an inherited cardiac condition.
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